ストックスクリーナーアプリを入手
18.66
2.02%
0.37
プレマーケット:
18.45
-0.21
-1.13%
前日終値:
$18.29
開ける：
$18.47
24時間の取引高:
3.27M
Relative Volume:
1.07
時価総額：
$58.95B
収益：
$29.85B
当期純損益:
$776.90M
株価収益率:
77.49
EPS:
0.2408
ネットキャッシュフロー:
$4.35B
1週間 パフォーマンス:
-0.59%
1か月 パフォーマンス:
+4.36%
6か月 パフォーマンス:
+30.40%
1年 パフォーマンス:
+32.72%
1日の値動き範囲:
$18.41
$18.75
1週間の範囲:
$18.07
$18.83
52週間の値動き範囲:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.66 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
119.75 | 50.55B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.97 | 44.44B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.52 | 35.54B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
581.69 | 25.49B | 3.18B | 1.33B | 1.04B | 27.90 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 再開されました | Morgan Stanley | Overweight |
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock HoldersInstitutional & Insider Ownership - GuruFocus
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Pharmaceutical (ADR) Stock: A Stable Global Pharma Play with Focus on Oncology and Rare Disea - AD HOC NEWS
Who's Buying or Selling Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock Today? - gurufocus.com
Takeda Pharmaceutical Co Ltd Stock Intrinsic Values | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Historical Valuations | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
What's Going On With Eli Lilly On Monday? - Benzinga
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical ADR sees IBD RS rating climb to 76 - MSN
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Finviz
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Stocks To Watch: Takeda Pharmaceutical ADR Sees Relative Strength Rating Rise To 83 - Investor's Business Daily
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
Apple, Visa, KLA-Tencor and more set to report earnings Thursday By Investing.com - Investing.com Nigeria
Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
US earnings seasonQ4 2025 - Interactive Investor
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
2.53%
大文字化:
|
ボリューム (24 時間):